2026年2月4日，GE 医疗发布 2025 年第四季度及全年业绩。 在全球医疗设备行业整体仍受宏观波动、贸易环境变化与成本压力影响的背景下，GE 医疗交出了一份 收 入与每股收益均超出市场预期 的年报，并同步给出了指向明确的 2026 年增长与利润修复指引。 这份年报的价值在于其所呈现出的 增长结构、盈利弹性以及对外部冲击的吸收能力 。 # 全年表现：收入温和增长，但"质量"并不保守 从全年结果看，GE 医疗 2025 年实现营收 206亿美元 （约合人民币1430亿） ，同比增长 4.8% ，其中 有机收入增长 3.5% 。 在大型医疗设备公司中，这一增速并不激进，但其来源具有相当明确的结构性支撑。 驱动增长的核心业务包括： 三大板块共同贡献了全年收入的主要增量，而非依赖单一明星产品或短期项目集中释放。 更重要的是订单端的表现： 在医疗设备行业，这一组合意味着两点： 一是收入增长并非"透支式兑现"；二是公司在手订单（backlog） 为 2026 年提供了较好的可见度。 但利润端则出现阶段性回落： Imaging（影像） Pharmaceutical Diagnostics（药物诊断，PDx） Advan ...

据介绍，辽宁医药产业既承载着服务国家战略、增进民生福祉的重要使命，也迎来了转型升级、跨越发 展的宝贵机遇。田东泉指出，面对新形势新任务，药监部门要以更大力度深化监管改革，为企业松绑减 负、激发创新活力；以更大力度加强法治建设，为企业提供公平公正、稳定可期的政策环境；以更大力 度强化服务保障，为企业提供便捷高效、精准可及的监管服务；以更大力度营造亲商重商氛围，为企业 提供开放包容、共赢共生的营商环境，当好产业发展的"服务员""护航员"。 田东泉强调，面对新机遇新挑战，辽宁省医药企业要专注主业、做优做强，筑牢高质量发展根基；要创 新突破、勇闯前沿，塑造产业竞争新优势；要严守法规、诚信经营，共建公平公正的市场生态；要心怀 大爱、奉献社会，在增进民生福祉中彰显担当，走好高质量发展之路，勇攀高峰、续写华章。 （文章来源：中国新闻网） 中新网沈阳2月2日电辽宁省药监与药企"面对面·心连心"座谈会2日在沈阳召开。 辽宁省药监局局长田东泉指出，过去的一年，辽宁省医药创新实力和质量显著提升，全国首台"光子计 数CT"落地辽宁，全球首创"心脏冷冻消融设备"在辽宁诞生，辽宁省医药制造业增加值增长4.1%，高于 辽宁省3.5个百分点 ...

Core Viewpoint - Shenyang aims for strategic emerging industries to account for 33.5% of the city's industrial output by 2025, marking a significant increase from previous years and indicating a shift towards innovation-driven economic growth [4][5]. Group 1: Economic Development and Industry Growth - The proportion of strategic emerging industries in Shenyang's industrial output has increased by 2.2 percentage points from the previous year and by 9.2 percentage points since 2020, surpassing the one-third threshold for the first time [5]. - Industrial technological transformation investment in Shenyang is projected to grow by 12.2% by 2025, with the number of technology-based enterprises exceeding 30,000 and "Four Up" enterprises surpassing 10,000 for the first time [5]. - Shenyang is focusing on nurturing new growth drivers while revitalizing traditional industries, aiming to build a resilient and secure modern industrial system [5][11]. Group 2: Technological Innovation and Product Development - Neusoft Medical has launched the first photon-counting CT in China and the world's first 8 cm wide-body photon-counting CT, positioning China as the third country to master this technology [8][10]. - The introduction of innovative products like the 1024-layer ultra-high-definition CT demonstrates Shenyang's commitment to technological advancement in the medical equipment sector [9][10]. - Shenyang's biopharmaceutical and medical equipment sectors are experiencing rapid growth, with companies focusing on innovation rather than price competition, leading to significant advancements in technology and product offerings [10]. Group 3: Strategic Industry Layout - Shenyang's industrial layout is defined by a "3+4+3" strategy, which includes optimizing traditional industries and nurturing four emerging sectors: aerospace, new-generation information technology, biomedicine, and new energy [11][12]. - The city is also focusing on future industries such as embodied intelligence, advanced materials, and deep-sea and deep-space equipment to secure a competitive edge [11][12]. Group 4: Policy Support and Economic Environment - New policies aimed at promoting digital economy development and reducing operational burdens for companies are set to take effect, enhancing the business environment in Shenyang [21][22]. - The "Intelligent Transformation and Digital Transition Action Plan" outlines measures to support manufacturing enterprises in their digital transformation efforts, with specific targets for 2027 [22][23]. - Shenyang is actively working to improve its investment environment and attract talent, aiming to create a city that is friendly to youth development and innovation [26].

Core Insights - The medical ETF (159828) has risen over 1%, indicating that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion [1] - The industry is expected to experience a convergence of industrial, policy, and capital cycles by 2026, transitioning from "innovation narrative" to "value realization," which may lead to performance inflection points and valuation restructuring [1] Industry Trends - The next generation of innovative therapies, including ADCs, bispecific/multispecific antibodies, cell and gene therapies, and small nucleic acids, are highlighted as key areas of focus [1] - The impact of centralized procurement on medical devices is diminishing, with over half of the policy coverage achieved; the coverage rates for high-value consumables, low-value consumables, in vitro diagnostics, and medical equipment are 58%, 35%, 23%, and 3% respectively [1] - Domestic medical device companies are making breakthroughs in high-end fields such as photon-counting CT and aortic regurgitation valves, with rapid growth in exports expected (medical device exports are projected to grow by 7.3% year-on-year from January to November 2025) [1] Investment Recommendations - Companies that can quickly achieve volume growth through price adjustments post-centralized procurement, as well as those benefiting from equipment upgrades driving procurement growth, are recommended for attention [1] - The medical ETF tracks the CSI Medical Index (399989), which selects listed companies in medical devices, medical services, and medical information technology, reflecting the overall performance of the medical theme [2] - The index is characterized by high growth attributes and industry concentration, influenced by aging trends, consumption upgrades, and policy guidance [2]

Core Insights - The article highlights the rise of domestic high-end medical devices in China, with a significant increase in innovation and production, supported by favorable policies and regulatory reforms [1][2][3] Industry Transformation - The high-end medical device industry in China is transitioning from reliance on imports to domestic production, with a focus on innovation and quality improvement [2][4] - The number of approved innovative medical devices reached 76 in 2025, maintaining a high level for three consecutive years, covering various advanced fields [1][2] Regulatory Support - The National Medical Products Administration (NMPA) has implemented reforms to streamline the approval process for innovative medical devices, enhancing efficiency and encouraging innovation [3][6] - Key measures include special reviews, priority approvals, and a focus on early-stage guidance for companies, which have significantly shortened the time from development to market [3][6] Breakthrough Innovations - Several notable products were approved in 2025, including a transcatheter aortic valve system and advanced imaging technologies, showcasing the capabilities of domestic companies to break import monopolies and achieve competitive technical standards [5][6] Market Integration - The improvement of the medical insurance system and procurement mechanisms has made high-end medical devices more accessible to grassroots hospitals, reducing costs and enhancing availability [6][7] - Since the 14th Five-Year Plan, 292 innovative medical devices have been approved, representing a 3.3-fold increase compared to the previous five-year period [6][7] Global Expansion - Chinese medical device exports accounted for approximately 8% of the global market in 2024, positioning China as the fourth-largest exporter [7] - Chinese companies are increasingly participating in international regulatory discussions and establishing overseas R&D centers, facilitating global market integration [7]

Core Points - The Liaoning May Day Labor Award ceremony was held on November 11, recognizing outstanding collectives and individuals in the province for their contributions to economic revitalization [1] - A total of 50 units, including Shenyang Yuanda Compressor Co., Ltd., received the Liaoning May Day Labor Award, while 400 workers, including Ma Chaoyang, were awarded the Liaoning May Day Labor Medal [1] - The event emphasized the importance of labor spirit and encouraged workers to actively participate in economic development and high-quality growth initiatives [1] Summary by Categories - **Recognition and Awards** - 50 units awarded the Liaoning May Day Labor Award, including Shenyang Yuanda Compressor Co., Ltd. [1] - 400 individuals awarded the Liaoning May Day Labor Medal, including Ma Chaoyang [1] - 50 collectives, such as the Neusoft Medical Photon Counting CT R&D team, received the Liaoning Worker Pioneer title [1] - **Call to Action** - Recognized collectives and individuals are urged to cherish their honors and continue their efforts [1] - Workers are encouraged to implement the decisions of the Central Committee and engage in economic construction [1] - Emphasis on overcoming challenges in major strategies, projects, and key industries to promote high-quality development [1] - **Leadership and Support** - Local party committees are called to enhance leadership over union activities and create favorable conditions for unions to fulfill their roles [1]

Core Viewpoint - Siemens Healthineers showcases its advanced technologies and strategic initiatives at the 8th China International Import Expo, emphasizing its commitment to local innovation and partnerships in the healthcare sector [1][11]. Group 1: Strategic Positioning - Siemens Healthineers maintains growth through a forward-looking strategy, focusing on "National Intelligence Innovation" and transitioning from a product provider to a value partner [2][5]. - The "National Intelligence Innovation" strategy emphasizes local production and innovation, with a goal of achieving full product line localization [4][11]. Group 2: Product and Innovation - The company has nearly achieved full localization of its product line, with plans for local mass production of photon counting CT devices by 2026 [4]. - Siemens Healthineers collaborates with local medical institutions to develop innovative solutions, creating a closed loop from clinical needs to product implementation [5][6]. Group 3: AI Integration - The company integrates AI deeply into its devices and clinical applications, showcasing advancements in AI-assisted diagnostics and imaging technologies at the expo [7][8]. - Siemens Healthineers aims to create an "automated driving" experience for imaging devices, enhancing efficiency and accuracy in clinical settings [8][10]. Group 4: Future Directions - The new five-year plan focuses on closer clinical integration, deeper collaboration, and sustainability, aiming to become a core partner in disease management and hospital administration [13]. - Siemens Healthineers is committed to fostering local innovation ecosystems and supporting the growth of domestic medical technology startups [12][11].

Core Insights - The China International Import Expo (CIIE) has evolved into a crucial platform for multinational companies to integrate into the Chinese market and share development opportunities since its inception in 2018 [1][14] - Siemens Healthineers has participated in the CIIE for eight consecutive years, showcasing its commitment to the Chinese market and emphasizing the importance of innovation and local collaboration [2][14] Company Strategy - Siemens Healthineers aims to combine global innovations with local clinical needs through its "National Intelligence Innovation" strategy, transitioning from global technology introduction to local innovation output [2][7] - The company has established a comprehensive medical ecosystem in China, focusing on R&D, production, clinical application, and patient care [7][8] Product Innovations - At this year's CIIE, Siemens Healthineers launched several groundbreaking products, including the new photon-counting CT family, which will enhance China's manufacturing capabilities in high-end medical equipment [3][4] - The ARTIS icono ceiling Xpand system significantly reduces imaging time in tumor interventions and stroke emergencies, improving clinical efficiency [6][12] Local Development - Siemens Healthineers has invested over 1 billion RMB in a new high-end medical equipment R&D and manufacturing base in Shenzhen, expected to triple its current scale by 2027 [7][8] - The company has localized over 130 products and filed more than 1,000 patents in China, demonstrating its commitment to local innovation [7][8] Market Potential - China is a key market for Siemens Healthineers, with a projected increase in the middle-income population from 400 million to 800 million over the next decade, driving demand for high-end medical services [12][14] - The company plans to focus on four core disease areas: cardiovascular diseases, cancer, neurodegenerative diseases, and stroke, aligning with national health strategies [12][13] Sustainability Efforts - Siemens Healthineers is committed to green and sustainable development, with initiatives like the DryCool technology that significantly reduces energy consumption and environmental impact [10][11] - The company aims for net-zero emissions by 2050 and is actively working on establishing green standards in the medical equipment industry [10][11]

Core Insights - The establishment of the Sci-Tech Innovation Board (STAR Market) has significantly enhanced China's capital market's ability to support technological innovation, with 592 listed companies and total fundraising exceeding 1.1 trillion yuan by October 2025 [1][3] - The STAR Market has demonstrated strong growth, with a compound annual growth rate (CAGR) of 18% in revenue and 9% in net profit for listed companies over the past five years [3][4] - The board has successfully fostered a vibrant ecosystem for hard technology, with over 80% of companies in emerging industries such as new-generation information technology and biomedicine [4][5] Company Performance - As of 2025, 22 out of 57 unprofitable companies listed on the STAR Market have achieved profitability, indicating a positive trend in financial performance [3] - The integrated circuit sector has over 120 listed companies, with revenue and net profit growth of 27% and 83% respectively in the first three quarters of 2025 [4] - In the biopharmaceutical sector, 21 out of 22 companies have received approval for 48 drugs/vaccines, contributing significantly to the innovation landscape [4] R&D Investment - The total R&D investment by STAR Market companies reached 1,680 billion yuan in 2024, more than three times their net profit [5] - In the first three quarters of 2025, R&D investment amounted to 1,133.45 billion yuan, a year-on-year increase of 9.01% [5] - The average number of invention patents per company on the STAR Market is 230, with 30% of companies having products or projects that are industry-first [5][6] Ecosystem Development - The STAR Market has created a virtuous cycle of "technology-industry-capital," enhancing the efficient allocation of innovative resources [7] - Over 60% of the founding teams of STAR Market companies consist of scientists or industry experts, fostering a strong innovation culture [7] - The market has seen a significant increase in cash dividend proposals, with a total of 38.8 billion yuan in dividends planned for 2024 [8] Institutional Innovation - The STAR Market has pioneered various institutional innovations, including diverse listing standards and mechanisms for rapid financing, which serve as a model for other markets [9] - Recent reforms have expanded the scope of the STAR Market to include more cutting-edge fields, enhancing its inclusivity [9] - The growth of the STAR Market's "growth layer" has accelerated, with companies showing revenue growth of 35.09% and a median R&D intensity of 44.34% [9] Future Outlook - The Shanghai Stock Exchange aims to further leverage the STAR Market as a testing ground for identifying high-quality tech companies, particularly in emerging fields like artificial intelligence and aerospace [10]

Core Viewpoint - The establishment of the Sci-Tech Innovation Board (STAR Market) has significantly contributed to the development of China's capital market, particularly in supporting technological innovation and the growth of "hard technology" companies over the past seven years [1][3]. Group 1: Market Development and Performance - As of October 2025, the STAR Market has gathered 592 listed companies, with a cumulative IPO fundraising scale of 934.6 billion yuan and total financing exceeding 1.1 trillion yuan, playing a crucial role in nurturing new productive forces and upgrading the modern industrial system [1]. - The compound annual growth rates for operating income and net profit attributable to shareholders of STAR Market companies over the past five years are 18% and 9%, respectively, indicating strong growth potential [3]. - Among the 57 unprofitable companies at the time of listing, 22 have achieved profitability, showcasing a trend of successful transitions from research and development to market success [3]. Group 2: Industry Focus and Innovation - The STAR Market has maintained a focus on "hard technology," with over 80% of listed companies in emerging industries such as new-generation information technology, biomedicine, and high-end equipment manufacturing [5]. - Key industries like integrated circuits and biomedicine have seen significant clustering effects, with over 120 listed companies in the integrated circuit sector, contributing to a complete and collaborative innovation ecosystem [6]. - In the integrated circuit sector, revenue and net profit for 119 companies that disclosed Q3 reports in 2025 grew by 27% and 83% year-on-year, respectively, with net profit for chip design companies soaring by 141% [6]. Group 3: Research and Development Investment - In 2024, total R&D investment by STAR Market companies reached 168 billion yuan, more than three times their net profit; in the first three quarters of 2025, R&D investment reached 113.3 billion yuan, a year-on-year increase of 9.01% [7]. - The STAR Market has generated over 130,000 invention patents, with an average of 230 patents per company, and 30% of companies have products or projects that are industry-first [7]. Group 4: Ecosystem and Capital Integration - The STAR Market has successfully established a virtuous cycle of "technology-industry-capital," enhancing the efficient allocation of innovative resources [10]. - Approximately 90% of STAR Market companies received venture capital investment before going public, indicating a strong trend towards early-stage investment in hard technology [11]. - The STAR Market has developed a comprehensive index system, with over 100 ETFs listed, and the total scale of index tracking products exceeding 330 billion yuan, making it a flagship index for hard technology investments [11]. Group 5: Institutional Innovation and Reforms - As a pioneer in the registration system reform, the STAR Market has implemented various innovative practices in issuance, listing, and trading, providing valuable experience for other market segments [14]. - Recent reforms, including the "1+6" measures, have further enhanced the inclusivity of the system, supporting the growth of companies in cutting-edge fields like artificial intelligence [14][15]. - The STAR Market has also accelerated the development of the "growth layer" for innovative companies, with significant increases in revenue and R&D investment among these firms [14].